Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


FORM 8-K

 


CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

March 30, 2006

Date of Report (date of earliest event reported)

 


HEMOSENSE, INC.

(Exact name of Registrant as specified in its charter)

 


 

Delaware   001-32541   77-0452938

(State or other jurisdiction of

incorporation or organization)

  (Commission File Number)  

(I.R.S. Employer

Identification Number)

651 River Oaks Parkway

San Jose, California 95134

(Address of principal executive offices)

(408) 719-1393

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 1.01. Entry into a Material Definitive Agreement.

On March 30, 2006 HemoSense, Inc., a Delaware corporation (“HemoSense”), entered into a Packaging Agreement (the “Agreement”) with J-PAC, LLC, a Delaware limited liability company (“J-PAC”). Pursuant to the terms of this Agreement, J-PAC will provide pouching, packaging, and shipping services to support HemoSense’s production of INRatio Test Strips in support of the INRatio PT/INR Monitoring System product line.

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits.

 

Exhibit No.   

Description

99.1    Press Release of HemoSense, Inc. dated April 5, 2006


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    HEMOSENSE, INC.
Date: April 5, 2006   By:  

/s/ James D. Merselis

    President and Chief Executive Officer


EXHIBIT INDEX

 

Exhibit No.   

Description

99.1    Press Release of HemoSense, Inc. dated April 5, 2006